MAGEL2 and Prader-Willi syndrome: Pilot clinical studies of OXT treatment in PWS and SYS infants have provided encouraging positive results (Tauber et al., 2017) and strong preclinical evidence on the effects of OXT treatment in Magel2-deficient animal models on biochemical and molecular parameters, including OXTR levels in the brain, is urgently needed.